Ftse Mib
34.490,71
0,07%
DAX
18.693,37
0,04%
S&P 500
5.304,72
0,70%
NASDAQ
16.920,79
1,10%
Bitcoin
68.748,39
0,32%

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Centessa Pharmaceuticals PLC (CNTA) Centessa Pharmaceuticals PLC (CNTA) Notizie

Centessa Pharmaceuticals PLC

CNTA
8,27
-0,08 (-0,96%)
25 Mag 2024 - Chiuso
Dati in Delay di 15 minuti
Borsa: NASDAQ
Tipo: Ricevuta di Deposito
Valuta: USD

Ultime notizie

Data Ora Fonte Titolo
21/5/202414:45GLOBECentessa Pharmaceuticals to Participate in Upcoming Investor..
13/5/202422:32EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
13/5/202422:23EDGAR2Form 8-K - Current report
13/5/202422:10GLOBECentessa Pharmaceuticals Reports Financial Results and..
09/5/202414:01EDGAR2Form ARS - Annual Report to Security Holders
09/5/202414:00EDGAR2Form DEF 14A - Other definitive proxy statements
24/4/202403:36GLOBECentessa Pharmaceuticals Announces Pricing of $100 Million..
23/4/202422:17GLOBECentessa Pharmaceuticals Announces $100 Million Proposed..
22/4/202413:00GLOBECentessa Pharmaceuticals Announces Open IND for ORX750;..
28/3/202421:28GLOBECentessa Pharmaceuticals Reports Business Highlights and..
22/2/202414:00GLOBECentessa Pharmaceuticals to Participate in TD Cowen’s 44th..
09/2/202413:12EDGAR2Form 8-K - Current report
09/2/202413:00GLOBECentessa Pharmaceuticals to Present Additional 52-Weeks of..
02/2/202423:10EDGAR2Form 4 - Statement of changes in beneficial ownership of..
02/2/202423:09EDGAR2Form 4 - Statement of changes in beneficial ownership of..
02/2/202423:07EDGAR2Form 4 - Statement of changes in beneficial ownership of..
02/2/202423:04EDGAR2Form 4 - Statement of changes in beneficial ownership of..
02/2/202423:03EDGAR2Form 4 - Statement of changes in beneficial ownership of..
01/2/202422:07EDGAR2Form 144 - Report of proposed sale of securities
22/1/202414:00GLOBECentessa Pharmaceuticals to Participate in Upcoming Investor..
09/1/202413:56EDGAR2Form 8-K - Current report
03/1/202401:46EDGAR2Form 4 - Statement of changes in beneficial ownership of..
03/1/202401:44EDGAR2Form 4 - Statement of changes in beneficial ownership of..
03/1/202401:43EDGAR2Form 4 - Statement of changes in beneficial ownership of..
03/1/202401:41EDGAR2Form 4 - Statement of changes in beneficial ownership of..
03/1/202401:37EDGAR2Form 4 - Statement of changes in beneficial ownership of..
13/12/202314:00GLOBECentessa Pharmaceuticals to Present at the 42ⁿᵈ Annual J.P...
11/12/202313:05EDGAR2Form 8-K - Current report
10/12/202318:05GLOBECentessa Pharmaceuticals Announces New Data from an..
27/11/202322:15GLOBEAnaptys Expands Immune Cell Modulator Pipeline with..
13/11/202322:22EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
13/11/202322:17EDGAR2Form 8-K - Current report
13/11/202322:05GLOBECentessa Pharmaceuticals Reports Financial Results and..
02/11/202314:09GLOBECentessa Pharmaceuticals to Present Additional 52-Weeks of..
31/10/202313:00GLOBECentessa Pharmaceuticals Announces Dosing of First Subject..
30/10/202313:00GLOBECentessa Pharmaceuticals to Participate in Upcoming Investor..
25/10/202315:49EDGAR2Form 8-K - Current report
25/10/202314:00GLOBECentessa Pharmaceuticals Announces Preclinical Data..
03/10/202323:00EDGAR2Form 4 - Statement of changes in beneficial ownership of..
03/10/202322:59EDGAR2Form 4 - Statement of changes in beneficial ownership of..
03/10/202322:53EDGAR2Form 4 - Statement of changes in beneficial ownership of..
03/10/202322:51EDGAR2Form 4 - Statement of changes in beneficial ownership of..
03/10/202322:46EDGAR2Form 4 - Statement of changes in beneficial ownership of..
03/10/202314:00GLOBECentessa Pharmaceuticals Announces Additions to Senior..
22/9/202322:47EDGAR2Form 4 - Statement of changes in beneficial ownership of..
20/9/202322:02EDGAR2Form 144 - Report of proposed sale of securities
01/9/202322:31EDGAR2Form 144 - Report of proposed sale of securities
31/8/202314:00GLOBECentessa Pharmaceuticals to Participate in the Morgan..
23/8/202323:08GLOBECentessa Pharmaceuticals to Present Preclinical Data for..
14/8/202313:18EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Apertura: 8,40 Min: 8,25 Max: 8,60
Chiusura: 8,35

La tua Cronologia

NASDAQ
CNTA
Centessa Pharmaceuticals
Delayed Upgrade Clock

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' SUL SITO CLICCARE QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network